Allogene Therapeutics Prices $175M Public Offering at $2.00/Share Following Positive Trial Results

summarizeSummary

Allogene Therapeutics priced its underwritten public offering of 87.5 million shares at $2.00 per share, aiming to raise $175 million, with an option for an additional $26.25 million, following recent positive Phase 2 trial results.

check_boxKey Events

• Public Offering Priced

  Allogene Therapeutics priced its underwritten public offering of 87,500,000 shares of common stock at $2.00 per share, expecting gross proceeds of $175.0 million.

• Underwriters' Option

  The company granted underwriters a 30-day option to purchase up to an additional 13,125,000 shares, potentially increasing gross proceeds by $26.25 million.

• Use of Proceeds

  Net proceeds are earmarked for general corporate purposes, including clinical trial expenses, research and development, and capital expenditures.

• Follows Positive Trial Results

  This financing event occurs immediately after the company reported positive interim futility analysis results from its pivotal Phase 2 ALPHA3 trial on April 13, 2026.

auto_awesomeAnalysis

This 8-K filing finalizes the terms and pricing of the public offering previously announced on April 13, 2026. Allogene Therapeutics priced its underwritten public offering of 87.5 million shares at $2.00 per share, aiming to raise $175 million, with an option for an additional $26.25 million. This represents a substantial capital raise, potentially up to $201.25 million, which is highly dilutive for existing shareholders. The offering is strategically timed immediately after the company reported positive interim futility analysis results from its pivotal Phase 2 ALPHA3 trial, allowing it to capitalize on improved investor sentiment. The net proceeds are designated for general corporate purposes, including critical clinical trial expenses, research and development, and capital expenditures, which is essential for a clinical-stage biotechnology company to extend its operational runway and advance its pipeline.